Respiratory syncytial virus pneumonia among the elderly: an assessment of disease burden
- PMID: 9841818
- DOI: 10.1086/314567
Respiratory syncytial virus pneumonia among the elderly: an assessment of disease burden
Abstract
Respiratory syncytial virus (RSV) is an important cause of acute lower respiratory tract disease among the elderly, but national estimates of the burden of this disease have not been made. To estimate the morbidity, mortality, and medical costs of RSV-associated pneumonia among US elderly, national hospital discharge data, vital statistics, etiologic studies of adult pneumonia hospitalizations, and Medicare cost data were reviewed. In the United States, 687,000 hospitalizations and 74,000 deaths caused by pneumonia occur annually among the elderly; approximately 2%-9% of these are caused by RSV. At a cost of $11,000 per RSV pneumonia hospitalization, the estimated annual cost of RSV pneumonia hospitalizations is $150-$680 million. Exacerbations of congestive heart failure and other chronic conditions may also contribute substantially to RSV disease burden among the elderly. The total RSV disease burden is probably great enough to justify development of an RSV vaccine for use in this group.
Similar articles
-
Respiratory syncytial virus pneumonia in the hospital setting: length of stay, charges, and mortality.J Pediatr. 2000 Aug;137(2):227-32. doi: 10.1067/mpd.2000.107525. J Pediatr. 2000. PMID: 10931416
-
Respiratory syncytial virus infection in elderly and high-risk adults.N Engl J Med. 2005 Apr 28;352(17):1749-59. doi: 10.1056/NEJMoa043951. N Engl J Med. 2005. PMID: 15858184
-
Respiratory syncytial virus-associated hospitalizations among infants and young children in the United States, 1997-2006.Pediatr Infect Dis J. 2012 Jan;31(1):5-9. doi: 10.1097/INF.0b013e31822e68e6. Pediatr Infect Dis J. 2012. PMID: 21817948
-
RSV infection in the adult population.Manag Care. 2008 Nov;17(11 Suppl 12):13-5, discussion 18-9. Manag Care. 2008. PMID: 19097558 Review.
-
Influenza and respiratory syncytial virus in the elderly.Expert Rev Vaccines. 2008 Mar;7(2):249-58. doi: 10.1586/14760584.7.2.249. Expert Rev Vaccines. 2008. PMID: 18324893 Review.
Cited by
-
Respiratory Viral Infections and Subversion of Cellular Antioxidant Defenses.J Pharmacogenomics Pharmacoproteomics. 2014 Sep 30;5(4):1000141. doi: 10.4172/2153-0645.1000141. J Pharmacogenomics Pharmacoproteomics. 2014. PMID: 25584194 Free PMC article.
-
Inhaled "Muco-Trapping" Monoclonal Antibody Effectively Treats Established Respiratory Syncytial Virus (RSV) Infections.Adv Sci (Weinh). 2024 Mar;11(12):e2306729. doi: 10.1002/advs.202306729. Epub 2024 Jan 15. Adv Sci (Weinh). 2024. PMID: 38225749 Free PMC article.
-
New insights for development of a safe and protective RSV vaccine.Hum Vaccin. 2010 Jun;6(6):482-92. doi: 10.4161/hv.6.6.11562. Epub 2010 Jun 1. Hum Vaccin. 2010. PMID: 20671419 Free PMC article. Review.
-
Gamma interferon-dependent protection of the mouse upper respiratory tract following parenteral immunization with a respiratory syncytial virus G protein fragment.J Virol. 2002 Oct;76(20):10203-10. doi: 10.1128/jvi.76.20.10203-10210.2002. J Virol. 2002. PMID: 12239295 Free PMC article.
-
Association between winter season and risk of death from cardiovascular diseases: a study in more than half a million inpatients in Beijing, China.BMC Cardiovasc Disord. 2013 Oct 30;13:93. doi: 10.1186/1471-2261-13-93. BMC Cardiovasc Disord. 2013. PMID: 24172216 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical